Trial Search Results
Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation
This research study is to determine if donor blood stem cells given after living, related, HLA antigen (Ag) haplotype match or living, unrelated, 3 HLA antigen matched (HLA-A, -B, and -DR) donor kidney transplantation will change the immune system such that immunosuppressive drugs can be completely withdrawn or reduced to minimal dose without kidney rejection.
Stanford is currently accepting patients for this trial.
Collaborator: California Institute for Regenerative Medicine (CIRM)
- Procedure: Immune tolerance after kidney transplant
- Drug: Donor blood stem cells and T cells
Early Phase 1
1. All consenting adults (18 years of age) living donor renal transplant recipients at
Stanford University Medical Center who have a one haplotype match donor.
2. Patients who agree to participate in the study and sign an Informed Consent.
3. Patients who have no known contraindication to administration of rabbit ATG or
4. Males and females of reproductive potential who agree to practice a reliable form of
contraception for at least 24 months posttranplant.
1. Previous treatment with rabbit ATG or known allergy to rabbit proteins.
2. History of malignancy with the exception of non-melanoma skin malignancies.
3. Pregnant women or nursing mothers.
4. Serological evidence of HIV, Hepatitis B or Hepatitis C infection.
5. Seronegative for Epstein-Barr virus , if donor is seropositive.
6. Leukopenia (with a white blood cell count < 3000/mm3) or thrombocytopenia (with a
platelet count < 100,000/mm3)
7. Panel Reactive antibody greater then 20% or demonstration of donor specific antibody
8. Prior organ transplantation.
9. High risk of primary kidney disease recurrence (i.e. primary FSGS).
Ages Eligible for Study
18 Years - 60 Years
Genders Eligible for Study